Mitotech SA
🇱🇺Luxembourg
- Country
- 🇱🇺Luxembourg
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
Phase 3
Completed
- Conditions
- Dry Eye Syndrome
- Interventions
- Drug: SkQ1 Vehicle SolutionDrug: SkQ1 Ophthalmic Solution
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Mitotech, SA
- Target Recruit Count
- 610
- Registration Number
- NCT04206020
- Locations
- 🇺🇸
Arizona Eye Institute and Cosmetic Laser, Sun City West, Arizona, United States
🇺🇸Eye Clinics of South Texas, San Antonio, Texas, United States
🇺🇸Piedmont Eye Center, Lynchburg, Virginia, United States
Study of SkQ1 as Treatment for Dry-eye Syndrome
Phase 3
Completed
- Conditions
- Dry Eye Syndrome
- Interventions
- Drug: SkQ1 (Vehicle)Drug: Low Dose - SkQ1Drug: High dose - SkQ1
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Mitotech, SA
- Target Recruit Count
- 452
- Registration Number
- NCT03764735
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
🇺🇸Cornea & Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Eye Research Foundation, Newport Beach, California, United States
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
Phase 2
Completed
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Drug: Placebo (Vehicle) opthalmic solutionDrug: Low Dose 0.155µg/mL SkQ1 ophthalmic solutionDrug: High Dose 1.55µg/mL SkQ1 ophthalmic solution
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Mitotech, SA
- Target Recruit Count
- 91
- Registration Number
- NCT02121301
- Locations
- 🇺🇸
Lawrence General Hospital, Andover, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath